Results from the DAPA-HF trial showed that the risk of worsening HF or cardiovascular mortality was significantly lower with SGLT-2i than with placebo, regardless of the presence or absence of T2DM, suggesting that the therapeutic role of SGLT-2i in HFrEF extends to patients beyond T2DM
While GLP-1 receptor agonist therapy leads to greater relative fat loss than lean mass loss, preserving muscle tissue requires adequate protein intake and resistance exercise during weight reduction
This direct contact may enhance local tissue effects beyond what systemic administration achieves
NLRX1 knockout aggravates lipopolysaccharide (LPS)-induced heart injury and attenuates the anti-LPS cardioprotective effect of CYP2J2/11,12-EET by enhancing activation of NF-B and NLRP3 inflammasome
New England Journal of Medicine , 385(6), 503-515
Hormone and metabolic modulators S5